235 related articles for article (PubMed ID: 35850450)
1. Management of Mild-to-Moderate Hypertriglyceridemia.
Pulipati VP; Brinton EA; Hatipoglu B
Endocr Pract; 2022 Nov; 28(11):1187-1195. PubMed ID: 35850450
[TBL] [Abstract][Full Text] [Related]
2. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
Fan W; Philip S; Granowitz C; Toth PP; Wong ND
Diabetes Care; 2019 Dec; 42(12):2307-2314. PubMed ID: 31575639
[TBL] [Abstract][Full Text] [Related]
3. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
4. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
5. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
Ito MK
Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
7. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
[TBL] [Abstract][Full Text] [Related]
8. Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease.
Brinton EA
Cardiol Clin; 2015 May; 33(2):309-23. PubMed ID: 25939302
[TBL] [Abstract][Full Text] [Related]
9. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
10. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
11. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
12. Fibrates, Hypertriglyceridemia, and CVD Risk: Where Do We Stand After the PROMINENT Trial for Triglyceride Lowering?
Chukwurah MI; Miller M
Curr Cardiol Rep; 2023 Sep; 25(9):987-992. PubMed ID: 37505399
[TBL] [Abstract][Full Text] [Related]
13. What is really new in triglyceride guidelines?
Hussain A; Al Rifai M; Hermel M; Slipczuk L; Virani SS
Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):73-80. PubMed ID: 36722448
[TBL] [Abstract][Full Text] [Related]
14. The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.
Case BC; Bress AP; Kolm P; Philip S; Herrick JS; Granowitz CB; Toth PP; Fan W; Wong ND; Hull M; Weintraub WS
J Clin Lipidol; 2019; 13(5):754-761. PubMed ID: 31427271
[TBL] [Abstract][Full Text] [Related]
15. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
Boden WE; Bhatt DL; Toth PP; Ray KK; Chapman MJ; Lüscher TF
Eur Heart J; 2020 Jun; 41(24):2304-2312. PubMed ID: 31872245
[TBL] [Abstract][Full Text] [Related]
16. Hypertriglyceridemia and cardiovascular risk reduction.
Jacobson TA; Miller M; Schaefer EJ
Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
[TBL] [Abstract][Full Text] [Related]
17. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
18. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
19. Hypertriglyceridemia: the importance of identifying patients at risk.
Kushner PA; Cobble ME
Postgrad Med; 2016 Nov; 128(8):848-858. PubMed ID: 27710158
[TBL] [Abstract][Full Text] [Related]
20. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
